Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review
- PMID: 25257544
- PMCID: PMC4301686
- DOI: 10.1111/bph.12944
Are cannabidiol and Δ(9) -tetrahydrocannabivarin negative modulators of the endocannabinoid system? A systematic review
Abstract
Based upon evidence that the therapeutic properties of Cannabis preparations are not solely dependent upon the presence of Δ(9) -tetrahydrocannabinol (THC), pharmacological studies have been recently carried out with other plant cannabinoids (phytocannabinoids), particularly cannabidiol (CBD) and Δ(9) -tetrahydrocannabivarin (THCV). Results from some of these studies have fostered the view that CBD and THCV modulate the effects of THC via direct blockade of cannabinoid CB1 receptors, thus behaving like first-generation CB1 receptor inverse agonists, such as rimonabant. Here, we review in vitro and ex vivo mechanistic studies of CBD and THCV, and synthesize data from these studies in a meta-analysis. Synthesized data regarding mechanisms are then used to interpret results from recent pre-clinical animal studies and clinical trials. The evidence indicates that CBD and THCV are not rimonabant-like in their action and thus appear very unlikely to produce unwanted CNS effects. They exhibit markedly disparate pharmacological profiles particularly at CB1 receptors: CBD is a very low-affinity CB1 ligand that can nevertheless affect CB1 receptor activity in vivo in an indirect manner, while THCV is a high-affinity CB1 receptor ligand and potent antagonist in vitro and yet only occasionally produces effects in vivo resulting from CB1 receptor antagonism. THCV has also high affinity for CB2 receptors and signals as a partial agonist, differing from both CBD and rimonabant. These cannabinoids illustrate how in vitro mechanistic studies do not always predict in vivo pharmacology and underlie the necessity of testing compounds in vivo before drawing any conclusion on their functional activity at a given target.
© 2014 The British Pharmacological Society.
Figures
Similar articles
-
Neuropharmacological Effects of the Main Phytocannabinoids: A Narrative Review.Adv Exp Med Biol. 2021;1264:29-45. doi: 10.1007/978-3-030-57369-0_3. Adv Exp Med Biol. 2021. PMID: 33332002 Review.
-
Evaluation of the potential of the phytocannabinoids, cannabidivarin (CBDV) and Δ(9) -tetrahydrocannabivarin (THCV), to produce CB1 receptor inverse agonism symptoms of nausea in rats.Br J Pharmacol. 2013 Oct;170(3):671-8. doi: 10.1111/bph.12322. Br J Pharmacol. 2013. PMID: 23902479 Free PMC article.
-
Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception.Drug Alcohol Depend. 2009 Nov 1;105(1-2):42-7. doi: 10.1016/j.drugalcdep.2009.06.009. Epub 2009 Aug 12. Drug Alcohol Depend. 2009. PMID: 19679411 Free PMC article.
-
The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9-tetrahydrocannabivarin.Br J Pharmacol. 2008 Jan;153(2):199-215. doi: 10.1038/sj.bjp.0707442. Epub 2007 Sep 10. Br J Pharmacol. 2008. PMID: 17828291 Free PMC article. Review.
-
Evidence that the plant cannabinoid Delta9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 receptor antagonist.Br J Pharmacol. 2005 Dec;146(7):917-26. doi: 10.1038/sj.bjp.0706414. Br J Pharmacol. 2005. PMID: 16205722 Free PMC article.
Cited by
-
Opportunities, Challenges, and Scientific Progress in Hemp Crops.Molecules. 2024 May 20;29(10):2397. doi: 10.3390/molecules29102397. Molecules. 2024. PMID: 38792258 Free PMC article. Review.
-
Differential effects of cannabis constituents on schizophrenia-related psychosis: a rationale for incorporating cannabidiol into a schizophrenia therapeutic regimen.Front Psychiatry. 2024 Apr 23;15:1386263. doi: 10.3389/fpsyt.2024.1386263. eCollection 2024. Front Psychiatry. 2024. PMID: 38716117 Free PMC article. Review.
-
Phytocannabinoids: Exploring Pharmacological Profiles and Their Impact on Therapeutical Use.Int J Mol Sci. 2024 Apr 10;25(8):4204. doi: 10.3390/ijms25084204. Int J Mol Sci. 2024. PMID: 38673788 Free PMC article. Review.
-
Effects of acute cannabidiol on behavior and the endocannabinoid system in HIV-1 Tat transgenic female and male mice.Front Neurosci. 2024 Mar 5;18:1358555. doi: 10.3389/fnins.2024.1358555. eCollection 2024. Front Neurosci. 2024. PMID: 38505774 Free PMC article.
-
A phase III multisite randomised controlled trial to compare the efficacy of cannabidiol to placebo in the treatment of cannabis use disorder: the CBD-CUD study protocol.BMC Psychiatry. 2024 Mar 4;24(1):175. doi: 10.1186/s12888-024-05616-3. BMC Psychiatry. 2024. PMID: 38433233 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources